Trending Assets
Top investors this month
Trending Assets
Top investors this month
$21.8MFollowers
AbCellera bounces off of $15 base, up 18% after 2q earnings call
Watching $ABCL bleed out from $60 to $15 was painful, and I picked up a small tranche of shares at $15.47 11 days ago thinking a bottom may have been in place.
ABCL provides research services on their drug discovery platform for antibody treatment protocols - and their primary partnership with Eli Lilly's antibody treatment for COVID was suspended because the Delta variant proved resistant. It may have caused investors to believe that antibody treatments are useless against the ever changing virus - but perhaps it is wrong to extrapolate from a small sample size of 1.
ABCL notes they have 138 programs underway.
Will look to see how the stock trades on Monday - and may layer on another tranche.
Here's their PDF link:
On the earnings call - they noted an acquisition of a mouse platform called Trianni:
In our Trianni platform, an acquisition which we completed in 2020, it continued to contribute directly to our top line, generating milestone payments of $1 million and licensing fees of approximately $300,000 in the quarter. That brings the total revenue from the Trianni platform in the first half of the year to over $20 million. The primary benefit of the Trianni platform of course lies in enhancing the technology stack of our discovery programs. And we continue to invest and develop the next generation of animals internally to expand those capabilities. And we're pleased to see the licensees succeed with the Trianni flagship mouse in their own programs.
Sounds like they got a good deal!
Already have an account?